Meeting
2015 ASCO Annual Meeting
Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC).
Authors
David I. Quinn
University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA
David I. Quinn , Charles G. Drake , Robert Dreicer , Emmanuel S. Antonarakis , Neal D. Shore , John M. Corman , Raoul S. Concepcion , Christopher Michael Pieczonka , Nancy N. Chang , Todd DeVries , Nadeem A. Sheikh , Daniel Peter Petrylak
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer
Sub Track
Prostate Cancer
Clinical Trial Registration Number
NCT01981122
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5040)
DOI
10.1200/jco.2015.33.15_suppl.5040
Abstract #
5040
Poster Bd #
32
Abstract Disclosures
Similar Posters
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.
First Author: Charles G. Drake
Poster
2016 Genitourinary Cancers Symposium
Sipuleucel-T (sip-T)–induced proliferative CD8+ T-cell responses to immunizing and secondary antigens.
First Author: Emmanuel S. Antonarakis
Poster
2024 ASCO Genitourinary Cancers Symposium
LORIKEET: A phase 2, randomized, open-label study of lorigerlimab plus docetaxel versus docetaxel alone in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Sumit Kumar Subudhi
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro